Deals channel feed

With new buy­out, J&J jumps back in on a sto­ried but trou­bled Holy Grail tar­get

4 years ago

Cash-strapped an­tibi­otics play­er En­ta­sis could go pri­vate with a small-dol­lar buy­out of­fer on the ta­ble

4 years ago

How UCB beat 2 oth­er bid­ders to land $1.9B buy­out of Zo­genix and its epilep­sy drug

4 years ago

Re­cent­ly stung by AAV, Sarep­ta dives a lit­tle deep­er in­to non-vi­ral de­liv­ery with newest li­cens­ing pact

4 years ago
Cell/Gene Tx

Ox­ford Bio­med­ica en­ters the AAV man­u­fac­tur­ing world, buy­ing Ho­mol­o­gy's in-house busi­ness

4 years ago
Cell/Gene Tx
Manufacturing

Un­der the gun with Aduhelm floun­der­ing, Bio­gen sells its stake in biosim­i­lars busi­ness for $2.3B

4 years ago

Biotech bears are maul­ing stocks as 2022 opens on a bleak note for in­vestors

4 years ago
Financing
Pharma

Eli Cas­din co-leads $250M in­fu­sion in­to mi­croflu­idics play­er that land­ed NIH fund­ing for Covid-19 test­ing

4 years ago
Financing
Outsourcing

So what ex­act­ly does Ver­i­ly do? A new deal with L'Oréal does­n't clear up much

4 years ago

Faced with in­tense in­vestor back­lash, Unilever now says $68B is its fi­nal of­fer for GSK con­sumer health­care busi­ness

4 years ago

UCB buys its way to epilep­sy show­down with Jazz with $1.9B Zo­genix ac­qui­si­tion

4 years ago

What kind of biotech start­up wins a $3B syn­di­cate, woos a gallery of mar­quee sci­en­tists and re­cruits GSK's Hal Bar­ron as CEO in a stun­ner? Let Rick Klaus­ner ex­plain

4 years ago
Cell/Gene Tx

British bil­lion­aire Mike Platt hops on board a Lon­don start­up look­ing at drug dis­cov­ery from a dif­fer­ent an­gle

4 years ago
Financing
Startups

Se­ma4 shells out $623M to scoop up a lead­ing di­ag­nos­tics play­er and its trove of da­ta

4 years ago

Hal Bar­ron keeps 23andMe close on GSK's side to find more genes the R&D team can go af­ter

4 years ago

An­ti­body leg­end Till­man Gern­gross in­tro­duces his lat­est com­pa­ny, with an In­novent deal al­ready lined up

4 years ago
Startups

Ready for an M&A fight? Af­ter GSK shunned $68B of­fer, Unilever says it's still in hunt for con­sumer health JV

4 years ago
Pharma

Vir ex­pands part­ner­ship with Gates Foun­da­tion, adding $50M for HIV and malar­ia an­ti­body re­search ini­tia­tive

4 years ago

Bio­phar­ma deal­mak­ers re­flect on last year's shifts in the mar­ket, as they gear up for an­oth­er 'ac­tive' year ahead

4 years ago

Af­ter nab­bing two AI-gen­er­at­ed mol­e­cules, As­traZeneca re­turns to Benev­o­len­tAI with new col­lab­o­ra­tion

4 years ago
AI

#JPM22 - Deal­mak­ing in 2022: What's Big Phar­ma look­ing for and what is it will­ing to pay?

4 years ago

Three years, a clin­i­cal hold and a death lat­er, Sarep­ta aban­dons part­nered piv­otal-stage gene ther­a­py

4 years ago
Cell/Gene Tx

Sanofi joins the al­pha-synu­cle­in band­wag­on, hand­ing Ko­re­an biotech $75M for pre­clin­i­cal bis­pe­cif­ic

4 years ago

Pfiz­er's hot start to the new year con­tin­ues with li­cens­ing deal for mys­te­ri­ous biotech's sol­id tu­mor bis­pecifics

4 years ago
First page Previous page 64656667686970 Next page Last page
A service from the Financial Times